| 18th week of 2011 patent applcation highlights part 51 |
| Patent application number | Title | Published |
|---|
| 20110104677 | SELECTIVE RESTRICTION FRAGMENT AMPLIFICATION: FINGERPRINTING - The invention relates to a process for the controlled amplification of at least one part of a starting DNA containing a plurality of restriction sites for a determined specific restriction endonuclease, and of which at least part of its nucleic acid is unknown. This technology can be applied to human, animal or plant DNA fingerprinting, to identify restriction fragment length polymorphisms. Also encompassed by the inventive technology are kits for the application of the process. | 2011-05-05 |
| 20110104678 | POLYMERASE INHIBITOR AND METHOD OF USING SAME - The present invention provides nucleic acid based polymerase inhibitors and methods for reducing non-specific polymerase extension and amplification in nucleic acid amplification reactions. The polymerase inhibitors provide a double stranded nucleic acid portion that is recognized by a polymerase enzyme as a template for extension but is incapable of being extended by the polymerase enzyme. The polymerase binds to the polymerase inhibitor which sequesters the enzyme until the temperature achieves a level that denatures the double stranded portion of the inhibitor after which the polymerase is released and can then catalyze nucleic acid extension. | 2011-05-05 |
| 20110104679 | Methods and Compositions for the Diagnosis and Treatment of Angiogenic Disorders - The invention provides methods and compositions for determining whether an individual is at risk of developing, or has, one or more angiogenic disorders. The methods detect the presence and/or amount of one or more genes or gene products in a sample, including a RORA, CRIM1, CXCR4, C5orf26, IGHG3, NALP2, PLA2G4A, IGLJ3, SHQ1, UCHL1, TANC1, PKP2, DNAJC6, C6orf105, NALP1, RGS13, CXCL13, RPS6KA2, MMP7, IL1A, ABCA1, VCAN, KIAA0888, ENPP2, and FAM38B gene or gene product. In addition, the invention provides methods for using one or more of these genes or gene products as a target for preventing or delaying the onset of one or more angiogenic disorders or treating a patient with one or more such disorders. The angiogenic disorder can be, for example, an ocular angiogenic disorder, for example, a disorder associated with choroidal neovascularization, for example, age-related macular degeneration. | 2011-05-05 |
| 20110104680 | RECURRENT GENE FUSIONS IN LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for lung cancer. | 2011-05-05 |
| 20110104681 | NOVEL TRANSGENE ASSAY USING STABLE AGROBACTERIUM RHIZOGENES TRANSFORMATION - A novel method is described for the screening of gene elements of interest using hairy roots of chimeric plants transformed with | 2011-05-05 |
| 20110104682 | RNA DETECTION ASSAYS - The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5′ nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. | 2011-05-05 |
| 20110104683 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME - The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. PAI-1 genotype screening may be useful in identifying patients who would benefit from increased monitoring by healthcare professionals, and/or possible therapeutic intervention, if the patient were to develop inflammation due to systemic inflammation response syndrome (SIRS), bacterial infection, bacteraemia, sepsis, septic shock, organ dysfunction, and trauma. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition. | 2011-05-05 |
| 20110104684 | Methods and Compositions for Identifying Sulfur and Iron Modifying Bacteria - The invention relates to methods and compositions for identifying specific bacterial species, which are sulfur and iron oxidizers and/or reducers, from wall board (e.g., dry wall) and/or a patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the bacterial species from the wall board and/or the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the bacterial species, and specifically identifying the bacterial species. Kits and nucleic acids for use in the methods are also provided. Methods for eliminating the sulfur and iron oxidizing and/or reducing bacteria from wall board using a zeolite are also provided. | 2011-05-05 |
| 20110104685 | METHOD FOR TESTING MICROORGANISM OR THE LIKE AND TESTING APPARATUS THEREFOR - A means for accurately counting desired cells or microorganisms (viable bacteria) in a sample fluid in which contaminants are included is provided. One or plural types of membrane-permeable fluorochromes whose fluorescence amount is amplified by binding to a nucleic acid and glycerin are added to a sample fluid containing cells or microorganisms to be counted and allowed to stand for a certain time. Glycerin is added before or after or simultaneously with the mixing of the sample fluid and the fluorochrome(s). The cells or microorganisms to be counted are counted by staining the cells or microorganisms to be counted, followed by irradiating with light having a specific wavelength to detect the fluorescence emitted from the cells or microorganisms. | 2011-05-05 |
| 20110104686 | RAPID DETECTION OF MYCOPLASMA CONTAMINATION IN CELL CULTURE SAMPLES - The present invention provides for methods of detecting | 2011-05-05 |
| 20110104687 | Methods and Kits for Detecting Congenital Stationary Night Blindness and Selecting Different Coat Patterns - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting congenital stationary night blindness in a subject. The present application also provides methods for selecting or detecting horse coat patterns. | 2011-05-05 |
| 20110104688 | MICROFLUIDIC FLOW CELL - A microfluidic flow cell having a body with a fluid transport channel disposed therein, the fluid transport channel having a proximal end and a distal end defining a fluid flow path, a fluid inlet port disposed at the proximal end of the fluid transport channel at a central portion of the body and an outlet port disposed at the distal end of the fluid transport channel at an outer portion of the body, and a plurality sample wells disposed in the fluid transport channel substantially perpendicular to the fluid flow path in the fluid transport channel. The microfluidic flow cell may have hundreds or thousands of individual, sub-microliter sample wells. The microfluidic flow cell can be filled by applying a flowable liquid to the inlet port and spinning the flow cell to cause fluid to flow into fluid transport channel. The microfluidic flow cells described herein can be used in a variety of applications where small sample size and/or a large number of replicates are desirable. | 2011-05-05 |
| 20110104689 | Single nucleotide polymorphisms and the identification of lactose intolerance - The present invention relates generally to methods, kits, genotyping and/or nucleic acid molecules associated with the identification of a predisposition for lactase persistence, lactase non-persistence, lactose tolerance and/or lactose intolerance. The methods of the present invention comprise in general determining the presence or absence of at least one variant allele having one or more single nucleotide polymorphisms within a gene associated with the expression of lactase-phlorizin hydrolase. The single nucleotide polymorphism is selected from the group consisting essentially of C-14010, G-13915 and G-13907, as measured from the start of the LCT gene. | 2011-05-05 |
| 20110104690 | ENGINEERED NITRILE HYDRATASE-PRODUCING BACTERIUM WITH AMIDASE GENE KOUCKED-OUT, THE CONSTRUCTION AND THE USE THEREOF - An engineered nitrile hydratase-producing bacterium and its construction method as well as its applications, wherein the engineered nitrile hydratase-producing bacterium is a mutant strain of an original nitrile hydratase-producing bacterium strain obtained by knocking-out or inhibiting the amidase gene in the original strain. The construction method of the engineered bacterium is to block the expression of the amidase gene by inserting the large fragment of a recombinant suicide plasmid carrying an amidase gene fragment into a wild-type strain through the homologous recombination between the recombinant suicide plasmid and the amidase gene of the wild-type strain. Compared to the corresponding wild-type bacterium strain, both the cell growth and the nitrile hydratase expression of the engineered nitrile hydratase-producing bacterium according to the invention are increased. In the process of catalyzing the hydration of acrylonitrile to produce acrylamide, the yield of the product, acrylamide, is significantly increased, while the yield of the by-product acrylic acid is significantly decreased. The engineered nitrile hydratase-producing bacterium of the present invention has wide application prospect in the production of acrylamide by microbiological process. | 2011-05-05 |
| 20110104691 | ANDROGENETIC ALOPECIA - The present invention relates to methods for testing for a predisposition or presence of androgenetic alopecia comprising testing a sample obtained from a prospective patient or from a person suspected of carrying a predisposition for androgenetic alopecia. The invention also relates to a genetic marker for androgenetic alopecia characterised in that the genetic marker is located in a chromosomal region of human chromosome 20p11 and wherein the genetic marker is selected from the group consisting of a single nucleotide polymorphism (SNP), variable number of tandem repeat (VNTR), microsatellites or short tandem repeats (STR). Further, the invention relates to a diagnostic composition for the detection of androgenetic alopecia or a predisposition therefore as well as to a kit. | 2011-05-05 |
| 20110104692 | Oligonucleotide Primers - Disclosed herein is a method of amplifying a target nucleotide sequence in 16S rRNA or in 16S rDNA that includes (a) contacting a sample comprising a 16S rDNA and/or the reverse transcription product of a 16S rRNA with an oligonucleotide primer comprising the nucleotide sequence of TCC TAC GGG AGG CAG CAG (SEQ ID NO 1) or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 1 and an oligonucleotide primer comprising the nucleotide sequence of CGG TTA CCT TGT TAC GAC TT (SEQ ID NO 2) or a nucleotide sequence capable of hybridising under high stringency conditions to the nucleotide sequence complementary to SEQ ID NO 2; and (b) performing a primer-dependent nucleic acid amplification reaction to amplify the target nucleotide sequence in the 16S rRNA or the 16S rDNA. | 2011-05-05 |
| 20110104693 | QUANTITATIVE NUCLEASE PROTECTION SEQUENCING (qNPS) - The present invention provides a new approach, quantitative Nuclease Protection Sequencing (qNPS™), for addressing several challenges that face sequencing and which provides improvements for research and diagnostic applications. The method uses a lysis-only nuclease protection assay to generate nucleic acid, e.g., DNA probes for sequencing, which can be coupled to gene-specific tags to permit the identification of the gene without necessitating the sequencing of the nuclease protection probe itself and/or can be coupled to experiment-specific tags whereby samples from different patients can be combined into a single run. The disclosed qNPS makes sequencing fixed or insoluble samples possible and affordable as a research and discovery tool and as a diagnostic test. | 2011-05-05 |
| 20110104694 | COMPOSITIONS AND METHODS FOR DETECTING CANCER - The present invention provides methods and compositions involving detecting the presence of and/or assessing the risk of cancer in a subject. These methods include methods of detecting and diagnosing cancer in an individual; methods of identifying individuals at risk of developing a cancer; and methods of staging a cancer. The methods generally involve detecting a palladin gene nucleotide sequence alteration that has been found to be associated with cancer and/or detecting a level of a palladin mRNA and/or protein in a biological sample. The present invention further provides nucleic acid probes, nucleic acid primers, and antibodies, as well as kits comprising one or more of the same, for use in a subject method. | 2011-05-05 |
| 20110104695 | METHODS OF PREDICTING THERAPEUTIC EFFICACY OF CANCER THERAPY - The present invention relates to novel methods and kits for predicting, prognosing, and/or monitoring therapeutic efficacy of cancer therapy on a subject having malignant tumor or cell proliferative disorder. | 2011-05-05 |
| 20110104696 | KIT FOR DETECTION OF BACTERIAL SPECIES BY MEANS OF DNA ANALYSIS - The present invention relates to the detection and identification of different bacterial species, all of which cause zoonosis, based on DNA analysis. More specifically, the invention provides the primers, probes, genes and genic regions required to apply a method for the simultaneous detection of bacteria and bacterial groups belonging to the genera | 2011-05-05 |
| 20110104697 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 2011-05-05 |
| 20110104698 | MARKERS FOR DETERMINING DNA DAMAGE AND TELOMERE DYSFUNCTION FOR THE DETERMINATION OF THE BIOLOGICAL AGE, REGENERATIVE CAPACITY, CANCER RISK, THE RISK OF DEVELOPING AGE-RELATED DISEASES AND THE PROGNOSIS OF CHRONIC DISEASES IN HUMANS AND ANIMALS - Process for determining the presence and extent of DNA damage and telomere dysfunction in humans or animals, comprising the following steps: | 2011-05-05 |
| 20110104699 | Method for Detection of Paecilomyces Variotii - A method of detecting | 2011-05-05 |
| 20110104700 | MOLECULAR SIGNATURE FOR FIBROSIS AND ATROPHY - Materials and Methods involved in assessing tissue fibrosis and atrophy in mammals. For example, materials and methods involved in detecting organ (e.g., kidney) fibrosis/atrophy due to organ rejection are provided, as are materials and methods for determining the extent of fibrosis/atrophy in mammals such as humans, for example. | 2011-05-05 |
| 20110104701 | PROTEIN DISULFIDE ISOMERASE ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the epitopes of sequence SEQ ID NO: 1, SEQ ID NO: 2 with an aromatic amino acid having a three-dimensional structure similar to that of PDI, and SEQ ID NO: 3. | 2011-05-05 |
| 20110104702 | Methods for Predicting Tumor Response to Chemotherapy and Selection of Tumor Treatment - Methods of selecting a treatment for further treatment of a tumor that has been exposed to chemotherapy and methods of predicting response of a tumor to chemotherapy are disclosed. Some of the methods involve performing gene expression analysis on a sample obtained from a patient having a tumor that has been exposed to chemotherapy so as to obtain a chemotherapy gene expression data set and analysing the chemotherapy gene expression data set to predict response of the tumor to the chemotherapy to which the tumor has been exposed. | 2011-05-05 |
| 20110104703 | NUCLEIC ACID ANALYZER, AUTOMATIC ANALYZER, AND ANALYSIS METHOD - This invention relates to a nucleic acid analyzer comprising: reaction containers capable of containing nucleic-acid-containing samples and reagents; an incubation mechanism capable of controlling temperatures of reaction containers set at different levels; an analysis mechanism for analyzing the samples contained in the reaction containers; and a transport mechanism for transporting a reaction container. In accordance with the assay technique to be performed on a nucleic-acid-containing sample, the transport mechanism transports a reaction container to a given incubation mechanism in a given order. The reaction container subjected to the process of sample preparation is transported to the analysis mechanism at a given time and the sample is analyzed. | 2011-05-05 |
| 20110104704 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF - The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject. | 2011-05-05 |
| 20110104705 | Musclin receptor and use thereof - The present invention provides a receptor of musclin and a screening system for an agonist and/or antagonist of the receptor by means of the interaction of musclin and the receptor. Hence, provided is a screening method for a substance that alters the bindability (i) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2 or a partial peptide thereof or a salt thereof and (ii) musclin or a partial peptide thereof or a salt thereof, containing using both. | 2011-05-05 |
| 20110104706 | NOVEL KINASES AND USES THEREOF - Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. | 2011-05-05 |
| 20110104707 | Methods and products for diagnosing autoimmune disease and gastric cancer linked with atrophic gastritis - The present invention relates to a method for examining a person having symptoms and/or biomarker indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods. | 2011-05-05 |
| 20110104708 | Method for Sensing a Chemical - The present invention relates to a method for detecting an analyte ( | 2011-05-05 |
| 20110104709 | POROUS SOLID PHASE FOR BINDING ASSAY, AND BINDING ASSAY METHOD USING THE SAME - A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant. | 2011-05-05 |
| 20110104710 | CONSTRUCTION OF EXPRESSION SYSTEM FOR RNA POLYMERASE DERIVED FROM INFLUENZA VIRUS, CRYSTALLIZATION OF THE RNA POLYMERASE, AND SCREENING METHOD FOR ANTI-INFLUENZA AGENT - The present invention aims to express influenza virus RNA polymerase on a large scale, to crystallize the influenza virus RNA polymerase, and to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs which target a protein highly conserved among influenza virus species. | 2011-05-05 |
| 20110104711 | GPR81-Ligand complexes and their preparation and use - Complexes of GPR81 receptor components and ligand components, such as L-lactate or GHB, may be used as an assay reagent for screening for modulators of GPR81 receptor activity. | 2011-05-05 |
| 20110104712 | Method for Assaying Plasma Enzymes in Whole Blood - The present invention relates to a method for assaying catalytic plasma enzymes, such as transaminases and NADH-dependent enzymes, in a sample of whole blood, by measuring, in a microfluidic chamber, the decrease in the fluorescence of NADH consumed during the enzymatic reactions catalyzed by the NADH-dependent enzymes. | 2011-05-05 |
| 20110104713 | PRODUCTS AND PROCESSES FOR MODULATING PEPTIDE-PEPTIDE BINDING DOMAIN INTERACTIONS - The present invention relates to therapeutic compounds and methods of use of these therapeutic compounds for treating cellular proliferative disorders. The invention also provides three-dimensional structures of a Polo-like kinase and methods for designing or selecting small molecule inhibitors using these structures, and the therapeutic use of such compounds. The invention also includes a method for identifying novel phosphopeptide-binding domains. | 2011-05-05 |
| 20110104714 | NON-PROTEOLYTIC METHOD FOR THE DETERMINATION OF ANALYTES IN KERATINIZED STRUCTURES - Methods that permit the rapid release of one or more analytes from head or body hair or other keratinized structures of an individual (who may previously have ingested one or more of the analytes) are provided. The methods can include contacting the keratinized structure with a reducing agent but not with a proteolytic agent. The methods can further include identification and quantification of the one or more analytes by known analytical techniques such as immunoassays. The described methods do not damage the analyte and do not cause harmful effects on a subsequently-used analyte detection probe (e.g., an antibody). | 2011-05-05 |
| 20110104715 | CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF - In accordance with the present invention, it has been discovered that the β-amyloid precursor protein (APP), and two APP-like proteins (APLP1 and APLP2) are proteolytically cleaved by caspases in the C terminus to generate an approximately 31 amino acid peptide. It has been further discovered that the resultant C-terminal peptide is a potent inducer of apoptosis. Both caspase-cleaved APP and activated caspase-9 is present in brains of Alzheimer's disease patients but not in control brains. These findings indicate that caspase cleavage of APP and APP-like proteins leads to the generation of apoptotic peptides, which may contribute to the neuronal death associated with Alzheimer's disease. Accordingly, there are provided compositions and methods for modulating apoptosis. | 2011-05-05 |
| 20110104716 | NOVEL METHOD FOR SCREENING BRAIN-ACTIVE COMPOUNDS - The invention relates to a novel screening method for brain-active substances and mixtures using hippocampal slices. | 2011-05-05 |
| 20110104717 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 2011-05-05 |
| 20110104718 | Analysis of Circulating Tumor Cells, Fragments, and Debris - The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods. | 2011-05-05 |
| 20110104719 | Methylarginine detection in cells and tissues - The present invention provides a method for identifying a biological sample as cancerous or normal by comparing the methylation status of arginine proteins in a test sample with the normal sample. A different level of binding or pattern of binding of antibodies which are specific for arginine containing proteins in their methylated state indicates an abnormal condition. | 2011-05-05 |
| 20110104720 | Detection of Analytes Present in Exosomes - The invention provides methods for detection in stored biological samples of PrPsc and other analytes that are present in exosomes. | 2011-05-05 |
| 20110104721 | Human ABO Blood Group-Binding Lactobacilli - screening methods were carried out using surface plasmon resonance spectrums and human intestinal mucin and blood group antigens as probes. A trial to set selection criteria in the above-mentioned methods of screening for lactobacilli was made to adapt the methods to mass screening, and it was discovered that lactobacilli compatible with ABO blood groups can be screened by setting 100 RU as a criterion for judging bacterial binding under certain conditions. Using 238 | 2011-05-05 |
| 20110104722 | METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2 - The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2. | 2011-05-05 |
| 20110104723 | BIOMARKERS - The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention. | 2011-05-05 |
| 20110104724 | BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE - A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein; | 2011-05-05 |
| 20110104725 | Method of Effecting Coagulation in a Droplet - The invention provides techniques for coagulating blood on a droplet actuator. The invention also provides methods of manipulating the coagulated blood including a variety of droplet operations that may be conducted using the coagulated blood. Further, the invention provides a variety of assays that make use of the coagulated blood or various blood samples as input. | 2011-05-05 |
| 20110104726 | Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function. | 2011-05-05 |
| 20110104727 | ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR FABRY DISEASE - Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone. | 2011-05-05 |
| 20110104728 | Biliverdin from a Non-Animal Source - Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed. | 2011-05-05 |
| 20110104729 | CELL CULTURE SYSTEM, CELL CULTURE METHOD, CELL CULTURE VESSEL AND METHOD FOR MANUFACTURING CELL CULTURE VESSEL - A cell culture system comprising a light source for emitting light, a light intensity regulator for regulating the light intensity of the light emitted by the light source, a cell activity-measuring device for measuring the activity of cells cultured on a photocatalytic film irradiated with the light, and an association device for associating the light intensity with the cell activity. | 2011-05-05 |
| 20110104730 | MESOSCALE BIOREACTOR PLATFORM FOR PERFUSION - Disclosed is a mesoscale bioreactor platform including two or more liquid reservoirs in fluid communication with a culture chamber which chamber is in fluid communication with an exit. The platform allows the chamber to be perfused with a flow of liquid from one or more of the liquid reservoirs. The integrated reservoirs for liquids remove the need for external supplies of liquid to the culture chamber during cell culture experiments requiring perfusion of liquids. Moreover, with two or more reservoir it is possible to supply the culture chamber with different types of liquids. | 2011-05-05 |
| 20110104731 | REACTION CASSETTE, ASSAY DEVICE, AND ASSAY METHOD - A reaction cassette for biochemical assay, a biochemical assay device including the reaction cassette, and a biochemical assay method performed by using the biochemical assay device are provided. The reaction cassette includes a first space, a second space, a third space, and an inner wall. The first space is configured to accommodate liquid and includes a first opening facing upward. The second space includes a second opening whose direction is perpendicular to the direction of the first opening. The first space and the second space are disposed such that when the reaction cassette is rotated, liquid in the first space can flow into the second space. The third space is located under the first space and includes a third opening whose direction is the same as the direction of the first opening. The inner wall connects the second opening and the third opening, which serves as a liquid flow channel between the second space and the third space. | 2011-05-05 |
| 20110104732 | SURFACE-STRUCTURED DEVICE FOR LIFE-SCIENCE APPLICATIONS - Embodiments of the invention relate a surface-structured device for life-sciences and a life-science method applying the surface-structured device. The surface-structured device has a substrate with a frontside surface corresponding to a first surface; and a plurality of protrusions arranged on the frontside surface. A shortest dimension of the protrusions at the junction from the protrusion to the front-side surface is smaller than 250 nm and at least a first group of the plurality of protrusions is arranged on a first planar area of the frontside surface in a first regular pattern in a plane of the first planar area of the frontside surface. Further embodiments relate to a stamper which may be used in the manufacturing method of the surface-structured device and a manufacturing method for surface-structured device. | 2011-05-05 |
| 20110104733 | Method for Increasing the Biomass and the Metabolic Activity of Microorganisms by the Combined Adjustment of the Oxidation-Reduction Potential and of the Oxygen Dissolved During the Fermentation Process - The invention relates to a method for cultivating microorganisms, particularly of the type that comprises the step of seeding a culture medium with one or more microorganism strains, and the step of cultivating the medium thus seeded, characterized in that it comprises, during the entirety or a portion of the cultivation, the two following and simultaneous adjustments: adjusting the amount of oxygen dissolved in the medium to a given dissolved-oxygen setpoint; adjusting the value of the redox potential Eh of the medium to a given setpoint value Eh. | 2011-05-05 |
| 20110104734 | NOVEL STRATEGY TO REDUCE LACTIC ACID PRODUCTION AND CONTROL PH IN ANIMAL CELL CULTURE - The present disclosure provides a method for culturing cells in exogenous lactic acid. Certain aspects of the present disclosure include the production of recombinant proteins, such as antibodies and fragments thereof. Certain aspects of the present disclosure also relate to methods of controlling lactic acid production, pH stability and osmolality in cell culture. | 2011-05-05 |
| 20110104735 | HUMAN OMENTAL MESOTHELIAL CELLS, METHODS OF ISOLATION AND USES THEREOF - The present invention discloses novel methods and omental, myocardial, liver, lung, renal, peritoneal, intestinal and pancreatic mesothelial cells which are useful for a number of procedures including drug discovery, co-culturing, cell therapy and bioassay. The invention provides a method for isolating these cells that improves upon the methods previously used and provides cells isolated in quantity. The present invention provides a list of secreted proteins from omentum mesothelial cells that can be utilized in the described cell based assays. | 2011-05-05 |
| 20110104736 | SELECTION OF ORGANISMS CAPABLE OF FERMENTING MIXED SUBSTRATES - The present invention relates to a method for selecting a strain of an organism capable of improved consumption of a mixed substrate comprising two or more carbon sources as compared to a reference strain of the organism, which method comprises: growing a population of the reference strain of the organism in the presence of the two or more carbon sources, wherein the number of generations of growth of the said population on each of the said carbon sources is at least about 50% of the number of generations of growth on the carbon source most preferred by the organism; and selecting the resulting strain of the organism, thereby to select a strain of the organism capable of improved consumption of a mixed substrate comprising the two or more carbon sources as compared to the reference strain of the organism. The invention also relates to strains of organisms selected using such a method. Strains of organisms identified using the selection method may be used in fermentation processes in which a mixed substrate is used. | 2011-05-05 |
| 20110104737 | Photometric measuring method for a sample liquid, a photometric measuring device, and a mixing container for a photometric measuring device - The invention relates to a mixing container ( | 2011-05-05 |
| 20110104738 | BLOOD VISCOSITY ANALYSIS - A blood analyzing device ( | 2011-05-05 |
| 20110104739 | BIOMARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS - The invention provides a method for diagnosing amyotrophic lateral sclerosis (ALS) in a subject, a method for assessing the effectiveness of a drug in treating ALS, and a method for determining the site of onset of ALS in a subject. Each method comprises (a) obtaining a sample from the subject, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. In some embodiments, the method comprises comparing the mass spectral profile of the sample to the mass spectral profile of a positive or a negative standard. | 2011-05-05 |
| 20110104740 | FLUORESCENT PROTEIN AND CHROMOPROTEIN - It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from | 2011-05-05 |
| 20110104741 | Screening Method for Inhibitors of Cancer Cell Invasion and Screening System Thereof - This invention relates to a screening method for an inhibitor to cancer cell invasion, comprising the steps of: (a) co-culturing cancer cells and a carcinoma-associated fibroblasts (CAFs) in a multi-chamber containing a upper-chamber, a lower-chamber and a porous filter separating the upper-chamber from the lower-chamber; in which each cancer cells and CAFs is inoculated into the upper-chamber and the lower-chamber of the multi-chamber, and then a candidate is added to the upper-chamber; and (b) measuring the number of cancer cells passing the porous filter. According to the screening system and screening method using the same, the inhibitor to cancer cell invasion is able to be screened in a high-throughput manner. | 2011-05-05 |
| 20110104742 | INTEGRATED SEQUENTIAL SAMPLE PREPARATION SYSTEM - The invention provides an integrated sequential sample preparation system using a sequential centrifuge for preparing samples for analysis. Methods of more efficiently preparing discrete samples sequentially for subsequent analysis are also provided. The apparatus and methods for sequentially preparing discrete samples provide improved operating efficiencies over conventional preparation processes that use batch centrifugation systems. Such advantages include reducing dwell time, increasing system throughput, reducing sample preparation system footprint, and improving precision of the analytical process. The integrated sequential preparation system with the integrated sequential centrifuge further provides the capability of handling critical or STAT samples without compromising the operating efficiencies achieved by preparing discrete samples in a sequential manner. | 2011-05-05 |
| 20110104743 | Dynamic Light Scattering for in vitro Testing of Bodily Fluids - A method of diagnosing a pathological condition by detecting microparticles in a sample of bodily fluid using dynamic light scattering (DLS) is disclosed. The detection of microparticles in the bodily fluid by DLS may be used as an indicator of existing disease, to evaluate a risk of disease, as well as to monitor the efficacy of a treatment for disease. | 2011-05-05 |
| 20110104744 | CELL ANALYZING APPARATUS AND CELL ANALYZING METHOD - A cell analyzing apparatus, comprising: a parameter obtaining section for obtaining a characteristic parameter from a cell in a measurement sample; an imaging section for capturing an image of the cell in the measurement sample; an analyzing section for counting a cell in which the characteristic parameter meets a predetermined requirement among the cells in the measurement sample as a counting target and generating output data based on a counting result; a display section for displaying an image of the cell meeting the predetermined requirement and the output data; and an input section for receiving an instruction to specify the image displayed on the display section, wherein the analyzing section excludes a cell relevant to the specified image from the counting target and regenerates the output data is disclosed. A cell analyzing method is also disclosed. | 2011-05-05 |
| 20110104745 | METHOD OF EXPRESSING RECOMBINANT PROTEIN IN CHO CELLS - Method for enhancing the transfection rate of a mammalian expression vector in CHO cells. | 2011-05-05 |
| 20110104746 | Diluting Solution For Suspension For Use In The Measurement Of Number Of Living Microbial Cells Contained In Sample, And Method For Measurement Of Number Of Living Microbial Cells - A dilution buffer for suspension and an enumeration method, which, for the measurement of the viable cell count of a microorganism contained within a sample, and particularly a powdered product such as a milk powder, yield more accurate measurement values than have conventionally been obtainable. A dilution buffer for suspension, used for preparing a suspension buffer of a sample when conducting a measurement of the viable cell count of a microorganism contained within the sample, wherein the dilution buffer contains polysorbates at a concentration of not less than 0.5%. Also, an enumeration method for a microorganism contained within a sample, the method including: preparing a suspension buffer of the sample using a dilution buffer for suspension containing polysorbates at a concentration of not less than 0.5%, and measuring the viable cell count of the microorganism contained within the suspension buffer. | 2011-05-05 |
| 20110104747 | Method of Concentrating Beads in a Droplet - Methods of concentrating beads in a droplet and/or loading beads on a fluidic device are provided, including among other things, a method of concentrating beads in a droplet, the method comprising: (a) providing a droplet actuator comprising: (i) an interior droplet operations volume; and (ii) a reservoir exterior to the interior volume; (iii) a droplet established in a liquid path extending from the reservoir into the interior volume; (b) providing magnetically responsive beads in the portion of the droplet which is in the reservoir; (c) magnetically attracting the magnetically responsive beads through the liquid path into the portion of the droplet which is in the interior volume; and (d) forming a droplet comprising one or more of the magnetically responsive beads in the interior volume. | 2011-05-05 |
| 20110104748 | PROCESS FOR THE PREPARATION OF BETA-LACTAM COMPOUNDS - The present invention describes a process for the synthesis of a semi-synthetic β-lactam compound from a nucleus and a side chain selected from the group consisting of D-phenylglycine and D-dihydro-phenylglycine in the form of a side chain ester and an enzyme catalyzing the coupling of the side chain ester to the nucleus characterized in that the side chain ester is not isolated as a solid intermediate. | 2011-05-05 |
| 20110104749 | MODIFIED YEASTS AND USES THEREOF, IN PARTICULAR FOR PRODUCING STEROID DERIVATIVES - The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20αHSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives. | 2011-05-05 |
| 20110104750 | Filamentous Fungi Having Reduced UDP-Galactofuranose Content - A filamentous fungal cell having reduced UDP-galactofuranose is provided. The fungal cell may, in certain embodiments, contain a nuclear genome comprising an inactivated UDP-galactopyranose mutase (UDP-galp mutase) gene and a recombinant nucleic acid for expression of a protein. Also provided are methods of producing a protein using the subject fungal cell, as well as methods of producing the subject fungal cell. | 2011-05-05 |
| 20110104751 | VARIANT FORM OF URATE OXIDASE AND USE THEREOF - The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases. | 2011-05-05 |
| 20110104752 | Variation of Recombinant Expression Titres By Optimising Bacterial Ribosome Binding Sites - The present invention provides a method for optimising the ribosome binding site of a promoter for the expression of a gene encoding a polypeptide of interest, placed under the control of said promoter. The invention also relates to a vector containing such optimised promoters, a prokaryotic host cell transformed by said vector, as well as a method for producing a recombinant protein of interest. | 2011-05-05 |
| 20110104753 | Soluble Recombinant Influenza Antigens - The present invention provides a recombinant soluble trimeric hemagglutinin (rHA) protein comprising a hemagglutinin ectodomain and an oligomerization domain. The rHA is produced as a soluble homotrimer, and may further comprises a signal peptide and/or an endoplasmic reticulum (ER) retention signal. The invention is also directed to nucleic acids encoding the rHA of the invention, as well as vectors and chimeric constructs comprising the nucleic acid. Methods of producing the rHA are also provided. The rHA described herein may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2011-05-05 |
| 20110104754 | CELL CULTURE MEDIUM - We describe a method of growing an animal cell in a culture medium, in which the culture medium comprises an elevated concentration of a thymidine family member, in which the growth or viability of the animal cell is increased as a result of the elevated concentration of the thymidine family member in the cell culture medium. Preferably, the cell culture medium comprises a semi-solid medium, which is a serum free or chemically defined medium. | 2011-05-05 |
| 20110104755 | Antibodies immunoreactive with mutant hydroxypenylpyruvatedioxygenase - Antibodies immunoreactive to mutant | 2011-05-05 |
| 20110104756 | HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM - Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca | 2011-05-05 |
| 20110104757 | Human anti-B7RP1 Neutralizing Antibodies - This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided. | 2011-05-05 |
| 20110104758 | RECOMBINANT CELL CLONES HAVING INCREASED STABILITY AND METHODS OF MAKING AND USING THE SAME - Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones. | 2011-05-05 |
| 20110104759 | ENZYMES FOR STARCH PROCESSING - The present invention relates to polypeptides comprising a carbohydrate-binding module amino acid sequence and an alpha-amylase amino acid sequence as well as to the application of such polypeptides. | 2011-05-05 |
| 20110104760 | METHODS AND COMPOSITIONS FOR IMPROVING EFFICIENCY OF NUCLEIC ACIDS AMPLIFICATION REACTIONS - The present invention provides methods and compositions for improving the efficiency of nucleic acid amplification reactions. The invention encompasses hybrid polymerases that show increased processivity over wild type polymerases as well as decreased exonuclease activity. The invention also encompasses methods, compositions and kits for conducting nucleic acid synthesis and amplification reactions in which non-specific amplification of primers is reduced. | 2011-05-05 |
| 20110104761 | THERMOSTABLE DNA POLYMERASE FROM PALAEOCOCCUS HELGESONII - There is provided a polypeptide having thermostable DNA polymerase activity and comprising or consisting of an amino acid sequence with at least 78% identity to | 2011-05-05 |
| 20110104762 | Detection probe acting by molecular recognition - The present invention relates to a detection probe acting by molecular recognition of a target sequence, comprising successively in the 5′-3′ direction:
| 2011-05-05 |
| 20110104763 | Sequential Addition of Short DNA Oligos In DNA-Polymerase-Based Synthesis Reactions - A method of fabricating a DNA molecule of user-defined sequence. The method comprises the steps of preselecting a multiplicity of DNA sequence segments that will comprise the DNA molecule of user-defined sequence, separating the DNA sequence segments temporally, and combining the multiplicity of DNA sequence segments with at least one polymerase enzyme wherein the multiplicity of DNA sequence segments join to produce the DNA molecule of user-defined sequence. Sequence segments may be of length n, where n is an even or odd integer. In one embodiment the length of desired hybridizing overlap is specified by the user and the sequences and the protocol for combining them are guided by computational (bioinformatics) predictions. In one embodiment sequence segments are combined from multiple reading frames to span the same region of a sequence, so that multiple desired hybridizations may occur with different overlap lengths. In one embodiment starting sequence fragments are of different lengths, n, n+1, n+2, etc. | 2011-05-05 |
| 20110104764 | METHOD FOR SYNTHESISING OMEGA-AMINO-ALKANOIC ACIDS OR THE ESTERS THEREOF FROM NATURAL FATTY ACIDS - The invention relates to a method for synthesizing ω-amino-alkanoic acids or the esters thereof from mono-unsaturated natural fatty acids comprising at least one step of forming the unsaturated diacid corresponding to the original fatty acid. | 2011-05-05 |
| 20110104765 | STEREOSELECTIVE SYNTHESIS OF METYROSINE - Provided herein are compositions including diastereomers in substantially diastereomerically pure form and enantiomers in substantially enantiomerically pure form, and processes for preparing them and converting them to metyrosine. | 2011-05-05 |
| 20110104766 | Use of Bacteria for the Production of Bioenergy - The present invention relates to composition and methods of producing bioenergy. More specifically, the invention relates to the use of bacterium of the genus | 2011-05-05 |
| 20110104767 | METHOD FOR PRODUCING POLYHYDROXYALKANOATE (PHAs) USING HALOBACTERIUM AND HALOBACTERIUM - Disclosed are a method for producing polyhydroxyalkanoates (PHAs) using a halobacterium belonging to the genus | 2011-05-05 |
| 20110104768 | METHOD FOR PRODUCTION OF POLYESTER COPOLYMER USING RECOMBINANT MICROORGANISM - The object of the present invention is to provide a method for efficiently producing a polyester copolymer consisting of 3HB and LA via microbial fermentation with the use of a sugar as a starting material. | 2011-05-05 |
| 20110104769 | IMPROVED YEAST STRAINS FOR ORGANIC ACID PRODUCTION - The present invention relates to the production of organic acids with yeasts that overexpress at least one sugar transporter. The yeast might express further genes related to the production of the desired organic acid. The organic acid is produced by cultivation of the yeast overexpressing a sugar transporter in an adequate culture medium, whereupon the desired organic acid is accumulated in the culture medium and subsequently purified to the desired degree by techniques known in the art. | 2011-05-05 |
| 20110104770 | PROCESS FOR CONTROLLING SULFUR IN A FERMENTATION SYNGAS FEED STREAM - Ethanol and other liquid products are produced from biomass using gasification of the biomass to produce a syngas containing CO2, CO, H2 and sulfur or sulfur compounds that passes the syngas to a fermentation step for the conversion of the CO and CO2 and H2 to ethanol. Sulfur and sulfur compounds in the syngas are used to satisfy sulfur demanded by bacteria in the fermentation step. A sulfur control additive is added to the gasification to control syngas sulfur and sulfur compounds at a desired concentration to meet bacteria sulfur demand. | 2011-05-05 |
| 20110104771 | PROCESS FOR THE PRODUCTION OF A DICARBOXYLIC ACID - The present invention relates to a process for the production of a dicarboxylic acid wherein a eukaryotic cell is fermented in a suitable fermentation medium. The invention further relates to a eukaryotic cell comprising a nucleotide sequence encoding an enzyme which catalyses the conversion of isocitric acid to succinic acid, and a nucleotide sequence encoding an enzyme which catalyses the conversion of glyoxylic acid to malic acid. | 2011-05-05 |
| 20110104772 | Method of Cultivating Yeast for Enhancing Pentitol Production - A method for culturing the yeast for enhancing pentitol production is provided. The yeast cultured according to the present disclosure is | 2011-05-05 |
| 20110104773 | PROCESSING METHOD FOR FRACTIONALLY CONVERTING PENNISETUM HYDRIDUM INTO FUEL ETHANOL WITH CO-PRODUCTION OF ELECTRICITY GENERATION AND PAPER PULP - The invention relates to a method for fractionally converting pennisetum hydridum into fuel ethanol with co-production of electricity generation and paper pulp, which comprises subjecting the pennisetum hydridum having been cut into segments to steam explosion treatment by utilizing a steam explosion device to obtain a steam explosion product, and said method is characterized in that it comprises the steps of: washing the steam explosion product with water to obtain fibers and water washing liquid containing a degraded hemicellulose, and separating and purifying the water washing liquid to obtain an xylo-oligosaccharide; fractionally teasing the fibers, and subjecting the obtained long fibers to an ethanol self-catalyzed pulping and then a bleaching treatment to obtain a paper pulp, and after recovering ethanol, obtaining an alcohol-soluble lignin by separation; preparing cellulase by a solid state fermentation, that is, taking the short fibers obtained by fractionally teasing as a fermentation substrate of | 2011-05-05 |
| 20110104774 | RECYCLING AND REUSE OF CARBON DIOXIDE FOR TEMPERATURE CONTROL OF A FERMENTATION PROCESS - Methods and apparatus for improving the fermentation process by controlling the temperature of the fermentation tanks. Waste byproduct carbon dioxide from the fermentation process is recycled and used as a coolant medium for the fermentation process. These methods and apparatus are particularly useful for maintaining temperatures of the fermentation process when applied to production of green ethanol from sugarcane. | 2011-05-05 |
| 20110104775 | Method to Increase the Ethanol Concentration from the Conversion of Lignocellulose - The present disclosure is related to a method for increasing the ethanol concentration from the conversion of lignocellulose. The pretreated solid residues are mixed with ethanol-containing broth from the fermentation of xylose hydrolysate by | 2011-05-05 |
| 20110104776 | PROCESSES FOR PRODUCING H2S USING SULPHUR-REDUCING BACTERIA - There is provided a process for producing H | 2011-05-05 |
